Selank

Research-Grade

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, engineered by researchers at the Russian Institute of Molecular Genetics for anxiolytic activity without the sedation, tolerance, or dependence profile of benzodiazepines. It has been marketed as a prescription drug in Russia since the early 2000s for generalized anxiety disorder. Western regulatory recognition is limited and controlled clinical trials are mostly published in Russian journals. Reported mechanism involves GABAergic modulation, BDNF expression, and enkephalin pathway effects. Administration is typically intranasal; the peptide does not survive oral digestion. Anxiolytic effects are reported as rapid (within 15–30 minutes) and consistent across the small published human cohorts.